Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ENLV Relative to the S&P 500

ENLV Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Enlivex Therapeutics Ltd. (NASD:ENLV) seasonal charts above shows that a Buy Date of November 23 and a Sell Date of February 20 has resulted in a geometric average return of 9.02% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 57.36% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

To download ENLV seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ENLV